Leslie Fernandez

As the Neuroscience Field Reimbursement Manager for WA, AK, ID, OR and Reno NV, I partner with healthcare provider (HCP) offices to reduce barriers to patient access and reimbursement. Trusted in-office resource providing guidance on insurance coverage, prescription status, program eligibility, and payer-related challenges associated with AbbVie’s oral migraine therapies. Collaborates cross-functionally with Patient Services and Market Access teams to share payer trend insights and support broader access strategies.

Recognized for strong collaboration, relationship-building, and practical reimbursement expertise that simplifies complex access issues into clear, actionable solutions for providers and staff. Recently honored with the “All For One AbbVie” Accomplish Award for presenting a successful Sales/FRM partnership strategy during the Sales/FRM Leadership Virtual Summit alongside district manager and sales partner Tijna Ruiz, highlighting the impact of effective cross-functional collaboration.

Sr. Specialty Representative, Psychiatry: 3/2023-current

• Launched a new indication for Vraylar in psychiatry, while growing core bipolar 1 business through patient identification and NBRx negotiation.
• Improved national territory rank from 90th to top 50th percentile. Prior territory weekly TRx average below 160, now averaging well over 200, with all time high of 253 in Q2 2024.
• Selected as 2024 District Sales Trainer and "Challenger champ."
• Nominated by DM to participate in the Sypher "Provider Pathways" tool focus group and presenting this new CRM feature at the upcoming Q3 regional POA.

Urology/Oncology Sr. Sales Specialist, WA & AK: 04/2022 -1/2023

• Account Management for Buy-and-Bill injectable, Lupron Depot, for Prostate Cancer. Customers included Oncologists, Radiology Oncologists, Urologists and entire Health Systems in both direct and indirect purchase channels.
• Impacted business in short time, evident by accounts increasing utilization of Lupron. Market Share Growth: direct business increase 2.1% to 51.3% and indirect business increase 1.8 % to 52.2% by Q3 end. 2022 Ranking through Q3 #21/87.
• Displaced 12/30/22 due to AbbVie multi-franchise RIF.

Executed a territory business plan to develop oncology sales targets, collaborated with strategic manufacturing and distribution partners, supported the needs of the medical practice clients as it related to oncology specialty medications and therapy management.

• 2021 President's Club Award Recipient. Ranked #3/58 in Nation with 46% First Fill growth and 118% to goal. Exceeded AARP goal at169% with 93 AARP Rxs vs goal of 55 YTD.
• Highly proficient at patient medication adherence/refill tracking and reimbursement pull-through as it pertains to Medicare D, Part B, and Commercial plans; assisting offices with Oncology funding through Foundations and manufacturer copay programs.
• 2020-2022 Fields Sales Trainer for Oncology Division. Conduct new hire training and continuing education via field and virtual training sessions. Provide "Train the Trainer" sessions to managers and identify field training needs, reporting back to leadership.
• Increased oncology referrals and revenue for HSSP/IOD through 340B programs.
• Completed Optum Management Development Program in 2021 and currently participating in UnitedHealth Group Emerging Leaders Program 2022.
• Proficient with Microsoft Teams, Power Point, Zoom, Webex, Salesforce.com, Tableau, Orbit, ScriptMed and EPS platforms.

Contracts:

• (12/2017- 4/2018) AbbVie Metabolics contract. Promotional responsibilities for Synthroid and AndroGel 1.62% in Endocrinology and Urology accounts. Leveraged sample inventory in efforts to maintain business while strategically adapting to rapidly changing and crowded market.
• (1/2017-12/2017) Valeant Pharmaceuticals contract. Re-Launch of ADDYI for HSDD in Women's Health to OBGYNs, UROGYNs, and therapists treating sexual dysfunction. Ranked #2 Top TRT TRx Change Leader post product launch, recognized nationally for sales growth 77% over 2016 market performance. 2017 Ranked #7/80

• 2 Product Launches : Stendra (new entry in ED market) and Natesto (intranasal gel) in crowded TRT market. Multiple Stendra Contest Winner for New Trx Q2-Q4. 2015 Ranking #21/101
• Managed complex reimbursement, proper procedural technique and coding for Buy-and-Bill injectable Testopel, and Orphan drug Xiaflex.
• Grew market share of flagship product Fortesta Gel (TRT) to #2 ranking by Q4 2015.
• Best Practice Success Story recognized and shared during national Urology Sales Call.

Full-time Parent/Homemaker (1/2006-3/2015)

Urology and Women's Health: (11/04-01/06) Promotional responsibilities for Ditropan XL for OAB and Elmiron for IC. Sales Advisory Board.

Psychiatry, Neurology, & Behavioral Pediatrics: (07/01-11/04)

2001 Promotion to CNS Specialty Rep based on successful Concerta Launch. Co-marketed Risperdal with Janssen. CNS Field Trainer and new hire mentor.

• 2002 J&J Management Leadership Program
• 2002 Sales Excellence Award for Seattle CNS Specialty Territory
• Western Psychiatric Convention 2003

Primary Care & Pediatrics: (12/99-07/01) Completed J&J comprehensive product knowledge and selling-skills training program for entry into pharmaceutical industry.

• Launched and Marketed: QVAR and Concerta; additional products: Floxin Otic, Benecol and OTC portfolio.

Completed detailed nutritional assessments of each patient based on health history, medical conditions and energy requirements. Documented clinical findings and entered pertinent health data for processing, recordkeeping and use by other medical professionals. Referred patients to appropriate outpatient settings for additional diet education and support.